Teaser Image

Webinar On Demand:

A Groundbreaking Technology for Vaccine Development: New Techniques in Viral Cytopathogenicity Assessment using Real-Time Cell Analysis

Traditional measurement of viral titers during vaccine development often involve cytopathic effect (CPE) quantification by plaque assays or tissue culture infectious dose (TCID50) assays, which are based on subjective visual interpretation of cell culture deterioration. These labor-intensive endpoint assays can only provide a snapshot of the infection process and the overall kinetics information is missing.

The xCELLigence Real-Time Cell Analysis technology, a unique, live cell assay that allows label-free and continuous tracking of CPE progression in virus-infected cells, provides a dramatically simplified workflow for diverse virology assays, including but not limited to:

  • Virus titer determination
  • Detection and quantification of neutralizing antibodies
  • Antiviral drug discovery and development
  • Quantitative comparison of fitness between different virus strains

Topics covered in this webinar:

  • xCELLigence Real-time virus-titration assay as an alternative method to the classical CCID50 assay
  • how the xCELLigence biosensors monitor CPEs
  • Virus titer determination and quantification of neutralizing antibodies
  • Evaluation of oncolytic virus efficacy and virus quality/fitness.

Featured Presentations:

Loic Benair
Associate Scientist
Sanofi Pasteur, France

xCELLigence: a new real-time and high-throughput tool for viral infectivity titration

The classical cell-culture methods, such as cell culture infectious dose 50% (CCID50) assays, are time-consuming, endpoint assays currently used during the development of a viral vaccine production process to measure viral infectious titers. However, they are not suitable for handling the large number of tests required for high-throughput and large-scale screening analyses. Impedance-based bio-sensing techniques used in real-time cell analysis (RTCA) to assess cell layer biological status in vitro, provide real-time data. In this talk, we will assess the RTCA virus-titration assay as an alternative method to the classical CCID50 assay during the development of viral vaccine product
 
 
 
 

Brandon Lamarche, Ph.D.
Senior Scientist
ACEA Biosciences

Monitoring Virus Cytopathic Effects in Real Time: Diverse Applications Ranging from Vaccine Development and Drug Discovery to Quantification of Neutralizing Antibodies

When infected by a virus, host cells typically display phenotypic changes (such as swelling, detachment, and lysis) that are collectively referred to as a cytopathic effect (CPE). Although CPEs can be a useful tool for monitoring viral infection, traditional methods like the plaque assay attempt to quantify CPEs manually, and are therefore labor-intensive, subjective, and suffer from poor reproducibility. Each of these challenges is overcome by the xCELLigence real time cell analyzer. Using gold biosensors embedded within the bottom of microplate wells, the xCELLigence instrument continuously monitors virus-induced changes in host cell number, cell size, cell-substrate attachment strength, and cell-cell adhesion ( barrier function). The high sensitivity and reproducibility, simple workflow, and real-time kinetics of this assay make it a powerful tool for diverse virology applications.

Your Personal Data

* This field is required


For full details of how we will treat your information please view our privacy policy: www.agilent.com/home/privacy-policy

For Research Use Only. Not for use in diagnostic procedures.